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Objectives. This study sought to examine the effects of magne-
sium on epicardial action potential duration in patients during
early myocardial ischemia.
Background. Magnesium has been shown to reduce arrhyth-
mias in experimental models of myocardial ischemia. Experimen-
tal and clinical observations suggest an effect on repolarization.
Methods. Patients undergoing elective coronary artery bypass
surgery were randomized (double blind) to receive intravenous
magnesium (n  10) or placebo (n  10). Patients were placed on
cardiopulmonary bypass and paced at 600 ms, and stable
monophasic action potentials were obtained. Ischemia was
achieved by aortic cross-clamping for 2 min while normothermia
was maintained.
Results. Serum magnesium levels increased from 0.60 0.03 to
1.69  0.07 mmol/liter (mean  SEM) in the magnesium group,
with no change in the placebo group. Epicardial temperature was
identical in the two groups and did not alter during ischemia. At
90% repolarization, initial action potential prolongation was
observed in the placebo group over the ﬁrst minute of ischemia
(282.0  6.0 to 294.0  4.8 ms) but not in the magnesium group
(278.3  5.9 to 274.5  7.4 ms). At 2 min of ischemia, action
potential duration was shorter in the magnesium group than in
the placebo group (258.1  5.5 vs. 281.3  5.9 ms, respectively,
p < 0.05).
Conclusions. Intravenous magnesium infusion altered the epi-
cardial action potential response to ischemia in patients. These
ﬁndings may have important implications in the pathogenesis of
arrhythmias in ischemic myocardium.
(J Am Coll Cardiol 1996;28:1765–9)
1996 by the American College of Cardiology
Alteration in the normal time course of ventricular repolariza-
tion, as occurs during early myocardial ischemia, is known to
predispose to arrhythmias (1). Magnesium has been shown to
reduce arrhythmias in experimental models of myocardial
ischemia (2,3) and to be clinically useful in the termination of
torsade de pointes ventricular tachycardia (4,5). Although the
underlying mechanisms are unclear, magnesium possesses
several actions that would suggest an effect on repolarization
(6). However, despite its potential importance, direct informa-
tion on the effects of magnesium during ischemia from the in
situ human heart is lacking.
This study therefore undertook to investigate the effects of
magnesium on action potential duration in the human epicar-
dium during myocardial ischemia.
Methods
Patients undergoing routine coronary artery surgery for
relief of ischemia with no angiographic evidence of anterior
wall motion abnormality were studied. Ethical approval was
obtained from the St. George’s Hospital Ethics Committee,
and all patients gave fully informed written consent.
Anesthesia and operation. Patients were anesthetized us-
ing a standard technique in all cases. Drugs used included
morphine, thiopentone, alfentanyl, pancuronium, suxametho-
nium, nitrous oxide and enﬂurane. All patients had continuous
electrocardiographic, arterial and central venous monitoring.
Routine cardiopulmonary bypass was used with a bubble
oxygenator (Bentley BOS10) primed with 2 liters of Hart-
mann’s solution (sodium chloride 0.6%, sodium lactate 0.25%,
potassium chloride 0.04% and calcium chloride 0.027%; com-
position/liter: Na 131 mmol, K 5 mmol, Ca2 2 mmol,
HCO3
 [as lactate] 29 mmol and Cl 111 mmol). An ascend-
ing aortic cannula and a single right atrial venous cannula were
placed in position, and perfusion proceeded at 2.4 liters/m2 per
min with a Shiley, Stockert or Gambro pump in the pulsatile
mode. Blood gases, sodium and potassium concentrations and
the activated partial thromboplastin time were estimated at
regular intervals during the operation. The temperature of the
patient was maintained at 37C until completion of the exper-
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iments, after which the patient’s temperature was cooled to
28C, and the operation continued as usual.
Magnesium infusion. Patients were randomized preopera-
tively in a double-blind manner, with matching for age, gender,
preoperative beta-adrenergic blocking agents and calcium an-
tagonists. Patients received either an intravenous infusion of
magnesium sulfate or normal saline. Magnesium sulfate was
given in a dose of 0.2 mmol/kg over 15 min, followed by
0.1 mmol/kg per h until completion of the experiments. In
addition, 4 mmol of magnesium sulfate (or an identical volume
of normal saline) was added to the 2 liters of pump prime
solution, making a ﬁnal concentration of magnesium in this
solution of 2 mmol/liter in patients randomized to receive
magnesium. The infusion was started after induction of anes-
thesia, at least 1 h before action potential measurements were
made. Baseline patient characteristics (Table 1), extent of
coronary artery disease and left ventricular function were
similar in the two patient groups. Venous blood samples were
taken preoperatively and at the onset of measurements for
estimation of serum magnesium concentration.
Monophasic action potential recordings. The monophasic
action potential (MAP) has been shown (7–9) to faithfully
reproduce the time course of changes in the duration and
conﬁguration of repolarization phases 1 to 3 of the transmem-
brane action potential. In addition, the MAP has been shown
(10,11) to provide a sensitive index of action potential duration
during ischemia in the human heart.
Monophasic action potentials were recorded using a special
pressure contact bipolar silver/silver chloride electrode. The
electrode was modiﬁed from an endocardial action potential
catheter, with an acrylic holder attached. The holder has
grooved sides to enable it to be held between the surgeon’s
index and middle ﬁngers and is bored out to make a cup 20 mm
in diameter and 5 mm in depth that houses the electrode. The
cup enables the electrode to be maintained perpendicular to
the epicardium. Contact between the reference electrode and
the epicardium is through a tight-ﬁtting sponge soaked in
physiologic (0.9%) saline, warmed to 37C, which encircles the
catheter. The design enables the electrode to be easily manip-
ulated to any desired recording site on the epicardium without
the need for direct vision and ensures no risk of damage to the
myocardium. In addition, it allows constant pressure of the
active electrode to be maintained on the epicardium through-
out the recording procedure. The electrode design has been
previously described in detail (12).
Signal processing. The resultant signals were recorded on
a Gould ES2000 (Gould Instrument Systems Ltd., Ilford,
Essex, U.K.) using a Gould universal ampliﬁer (model 13-
4615-58) and a Gould electrophysiology lead selector, includ-
ing a patient isolator (model 11-1606-01). Hard-copy record-
ings were made on a Gould electrostatic recorder (model
ES2000EW) at a paper speed of 250 mm/s.
Protocol. Once the patient was placed on full bypass,
pacing wires were attached to the right atrial and right
ventricular epicardium. Pacing was commenced at a cycle
length of 600 ms from the right atrium, and if conduction
disturbances occurred, a right ventricular site was used. Action
potentials were recorded on the left ventricular epicardium
between the left anterior descending artery and its ﬁrst diag-
onal branch. When adequate MAP signals could not be
obtained from this site, the circumﬂex artery territory was
used.
When the patient is on cardiopulmonary bypass, oxygen-
ated blood enters the aortic arch from the bypass circuit to
supply the systemic circulation and also passes retrogradely to
supply the coronary arteries. Once stable pacing and left
ventricular action potentials were obtained, the heart was
made ischemic by cross-clamping the aorta between the return
of the bypass circuit in the ascending aorta and the coronary
arteries for a period of 2 min, thereby preventing coronary
ﬁlling but preserving the systemic circulation (10). Epicardial
temperature was measured at 15-s intervals during the
recording procedure using a needle probe inserted superﬁ-
cially into the subepicardium at a site adjacent to the MAP
catheter (model MKG-09500-A, Ellab UK Ltd., King’s
Lynn, Norfolk, U.K.).
Data analysis. Recordings of action potentials were mea-
sured (in ms) at 90% repolarization (APD90) with a tangent
drawn from the fastest part of the downstroke (Fig. 1), at
15-s intervals during the episode of ischemia (paper speed
250 mm/s) without knowledge of randomization results. To
Abbreviations and Acronyms
APD90  action potential duration at 90%
repolarization
ATP  adenosine triphosphate
Ito  transient outward current
MAP  monophasic action potential
Table 1. Clinical Characteristics of Two Study Groups
Placebo
Group
(n  10)
Magnesium
Group
(n  10)
Age (yr) (mean  SD) 59.0  2.7 60.3  4.5
Male 7 8
Angina (yr) (median) 4.7 3.6
Previous MI
Inferior 3 2
Anterior 2 2
Preop drugs
Beta-blocker 6 6
Ca antagonist 8 7
Nitrates 8 6
Coronary anatomy
LMCA involvement 4 3
2-vessel disease 3 2
3-vessel disease 3 5
Distal grafts (median) 4 3
Data presented are number of patients, unless otherwise indicated. Ca 
calcium; LMCA  left main coronary artery; MI  myocardial infarction;
Preop  preoperative.
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provide an indication of the relative changes in the “notch” at
the end of phase 1 repolarization and the plateau, a ratio was
measured as shown in Figure 1. When the plateau was reduced
to below the notch, no value was recorded. The data were
entered into an IBM-compatible computer and analyzed using
SAS software (SAS Institute Inc.). Data were compared using
two-way analysis of variance (split-plot design), the two factors
being the magnesium group and time with repeated measures
on time. In addition, pairwise comparisons were made using
Dunnet’s test, and the Bonferroni correction was used for
multiple t tests for comparing the magnesium and placebo
groups at different time periods as appropriate. For compari-
son of magnesium levels in the two groups, the unpaired t test
was used. Results are expressed as mean SEM or median, as
appropriate; p  0.05 was considered signiﬁcant.
Results
Monophasic action potentials were recorded from the left
ventricular epicardium during ischemia in 20 patients (10
randomized to receive magnesium, 10 placebo). The proce-
dure was uneventful and easily performed in all patients.
Figure 2 shows MAP recordings from a representative patient
(randomized to receive magnesium) obtained during the 2-min
ischemic period.
Infusion of magnesium resulted in an increase in serum
magnesium levels from 0.60 0.03 to 1.69 0.07 mmol/liter in
patients randomized to the magnesium group (p 0.001), with
no change in the placebo group (0.62  0.04 to 0.66 
0.05 mmol/liter). The magnesium infusion was well tolerated in
all patients and had no effect on heart rate or blood pressure
before institution of cardiopulmonary bypass. Epicardial tem-
perature was identical in the two groups and did not alter
during ischemia (placebo group: 35.7  1.2C at 0 s, 36.1 
0.7C at 60 s, 36.3  1.3C at 120 s; magnesium group: 35.9 
1.0C at 0 s, 36.2  0.9C at 60 s, 36.0  1.1C at 120 s).
Action potential changes. There was no difference in mean
APD90 at the onset of ischemia in the two groups (placebo
group: 282.0  6.0 ms, magnesium group: 278.3  5.9 ms).
During early ischemia, mean values for APD90 increased in the
placebo group (Fig. 3), reaching a maximum of 294.0  4.8 ms
at 1 min of ischemia. Between 1 and 2 min of ischemia, APD90
returned to near control values (281.3  5.9 ms). In the
magnesium group, the initial prolongation during the ﬁrst
minute of ischemia was absent, showing a small but nonsignif-
icant shortening from 278.3  5.9 ms at 0 s to 274.5  7.4 ms
at 1 min. At 90 s of ischemia, APD90 was signiﬁcantly shorter
than control values (p  0.05), and at 2-min of ischemia,
APD90 had shortened to 258.1  5.4 ms.
The difference in amplitude between the dip at the end of
phase 1 repolarization and the plateau was expressed as a
percent of the plateau amplitude (Fig. 1). Values at baseline
were 10.92  2.5% and 13.4  4.1% in the placebo and
magnesium groups, respectively (p  NS). These values were
not signiﬁcantly altered after 1 min of ischemia (12.8  5.4%
vs. 13.9  2.4%, respectively). After 2 min of ischemia, there
Figure 1. Method of MAP measurement, with diagrammatic repre-
sentation of a MAP. The duration of the action potential was
measured (in ms) at 90% repolarization (APD90) using a tangent
drawn from the fastest part of the repolarization phase. In addition,
the amplitude of phase 1 was measured and expressed as a percentage
of plateau amplitude, using the following formula: 100  (B  A)/B.
Figure 2. Monophasic action potential duration changes in a patient
randomized to receive magnesium infusion, illustrating characteristic
shortening of APD90 (shown in ms) during the 2-min period of
ischemia. Note that there was marked interpatient variability in the
plateau shape changes (see text).
Figure 3. Monophasic APD90 in patients randomized to receive either
placebo (solid circles) or magnesium (open circles) during a 2-min
period of global ischemia (mean values  SEM [vertical bars]). By
analysis of variance, there was a signiﬁcant effect of time (F value
34.71, p  0.0001) and an interaction effect between time and the
magnesium group (F value 32.32, p  0.0001). *p  0.05, magnesium
versus placebo. **p  0.05 versus control value.
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was wide variation in the dip and plateau conﬁguration; in ﬁve
patients in each group, the plateau decreased to a level below
the dip.
Discussion
To our knowledge, this is the ﬁrst study to investigate the
electrophysiologic effects of elevating serum magnesium levels
during ischemia in the human heart. In patients receiving
placebo, APD90 showed initial prolongation at 1 min of
ischemia and subsequent shortening to values similar to con-
trol levels after 2 min of ischemia. This prolongation was offset
by magnesium, a drug that has been shown (13, 14) to be
potentially beneﬁcial during myocardial ischemia and reperfu-
sion. In the magnesium group, there was no initial prolonga-
tion of action potential duration during ischemia, and by 2 min
of ischemia, action potential duration was substantially shorter
than control values.
Before considering the possible signiﬁcance of our ﬁndings,
some methodologic aspects need to be addressed. It is well
known that cooling prolongs the action potential (15). In our
study, care was taken to preserve normothermia during the
ischemic period, and thus temperature change should not have
inﬂuenced the comparison of action potential durations be-
tween the two groups.
Alterations in ventricular loading are known to inﬂuence
action potential duration (16). When the patient is placed on
cardiopulmonary bypass, blood is diverted from the lungs and
into the bypass circuit through the right atrial cannula. The left
ventricle is therefore converted from a “working” (i.e., sup-
porting the circulation) to a “nonworking” state, being only
partially ﬁlled. The interruption of coronary artery ﬂow may
also inﬂuence the mechanics of myocardial contraction by
altering wall stiffness. Thus, we cannot exclude the possibility
that mechanical factors may have inﬂuenced action potential
duration (16), although any such effects would be expected to
be similar for the two groups of patients studied.
Potential mechanisms. The mechanisms underlying the
observed effects are at present unclear. Magnesium is known to
have multiple effects on cellular ion channels. Increased mag-
nesium levels have been shown (6) to inﬂuence several potas-
sium currents, in general tending to result in a decrease in
these currents. For example, magnesium is partly responsible
for the characteristic of the inward rectiﬁer of not conducting
outward current at more positive potentials due to plugging of
the pore by magnesium ions (17). Several studies (6) have
shown a depressant effect on the delayed rectiﬁer current by
increases in magnesium concentration in the physiologic range.
The adenosine triphosphate-sensitive potassium channel (IK-
ATP), possibly not operative during the short period of isch-
emia in our studies, has been shown (18) to be blocked by
magnesium in a voltage-dependent manner. The effect of
magnesium on the transient outward current (Ito) remains to
be clariﬁed. The amplitude of phase 1 repolarization has been
shown (19,20) to be a measure of Ito. Unfortunately, the MAP,
as used in our study, is unreliable as a measure of amplitude,
particularly amplitude of the upstroke. Consequently, a quan-
titative measure of phase 1 amplitude was not accessible to us
as a means of estimating Ito. However, these technical aspects
of MAP recording would not be expected to inﬂuence the ratio
of the dip to the plateau amplitude (7–9). Because an interac-
tion between Ito and plateau potentials during ischemia have
been demonstrated by Lukas and Antzelevitch (19) and
Litovsky and Antzelevitch (20), we used a ratio of dip to
plateau as an indirect index of the inﬂuence of Ito. We found
no difference between the placebo and magnesium groups;
however, the variability within each group after 2 min of
ischemia was considerable.
Alternatively, magnesium is known to inhibit cellular and
sarcolemmal calcium ﬂux (21–23). For example, cells dialyzed
with 1.3 mmol/liter of internal magnesium ions exhibited
50% of the current generated by the cells dialyzed with
magnesium ion-free solutions (21). This effect on the calcium
channel was shown (21) to shorten action potential duration,
which would be in keeping with calcium currents being the
main mediator of the cellular actions of magnesium in the
setting of the present study.
Clinical implications. Alteration in action potential dura-
tion in the setting of ischemia may be proarrhythmic or
antiarrhythmic by a variety of mechanisms. Extrapolation of
our data to a regionally ischemic heart suggests several possi-
bilities (Fig. 3). Equating APD90 at time 0 s with the normal
zone (which does not change during ischemia) and APD90 at
120 s with the ischemic zone implies a greater dispersion of
APD between normal and ischemic zones in the presence of
elevated magnesium levels (compare APD90 at times 0 and
120 s for each group). It is therefore conceivable that the
apparent exaggerated shortening of action potential duration
at 2 min of ischemia could facilitate arrhythmias generated by
local current ﬂow (1). However, another scenario might be as
follows: In normal myocardium, refractoriness approximates
the action potential duration, but during ischemia, refractori-
ness outlasts action potential duration (postrepolarization
refractoriness). Again, equating time 0 with the normal zone
after 2 min of regional ischemia and time 120 s with 2 min of
ischemia in the ischemic zone, it follows from Figure 3 that the
development of postrepolarization refractoriness would in-
crease dispersion between the normal and ischemic zones in
the placebo group, with a decrease in dispersion in the
magnesium group.
It is therefore tempting to speculate that in the presence of
normal magnesium levels, refractoriness may be more dissim-
ilar between ischemic and nonischemic regions than in the
presence of elevated magnesium levels, and this dissimilarity
may be a potential mechanism for the observed antiarrhythmic
properties of magnesium in experimental studies of myocardial
ischemia.
The observations that we presented were limited to 2 min of
ischemia, and experimental studies have shown (1) that ar-
rhythmias are relatively uncommon during this time course,
probably because the electrophysiologic changes are not yet
sufﬁciently large. However, the second interpretation that we
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proposed (the protective effect) would be anticipated to re-
main operative after the 2-min period and into the time frame
during which type 1a arrhythmias occur (1).
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